 CAMBRIDGE, Mass., Oct. 14, 2021 PRNewswire -- Omega Therapeutics, Inc. Nasdaq: OMGA Omega, a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic ProgramingTM platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers OECs to control ocular disease genes associated with inflammation or regeneration of ocular tissues. 